Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunosuppressant drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:affects |
lymphocyte migration
|
| gptkbp:alsoKnownAs |
gptkb:Fingolimod
|
| gptkbp:approvedBy |
gptkb:FDA
2010 |
| gptkbp:ATCCode |
gptkb:L04AA27
|
| gptkbp:CASNumber |
gptkb:162359-55-9
|
| gptkbp:chemicalFormula |
C19H33NO2
|
| gptkbp:contraindication |
pregnancy
patients with heart block |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:discoveredIn |
1992
|
| gptkbp:eliminationHalfLife |
6-9 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
FTY720
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Gilenya
|
| gptkbp:mechanismOfAction |
sphingosine-1-phosphate receptor modulator
|
| gptkbp:metabolism |
CYP4F2
|
| gptkbp:origin |
synthetic analog of myriocin
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:macular_edema
bradycardia increased risk of infections |
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Fingolimod
|
| gptkbp:bfsLayer |
6
|